Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMIgFUS and HMIgLIFU for Breast Tumors
NCT05219695Phase 1Recruiting
- Sponsor
- Columbia University
- Start
- Jan 2022
- Primary completion
- May 2031
- Countries
- 1
01
Overview
Phase 1, open-label trial in fibroadenoma and breast cancer (2 arms), sponsored by Columbia University. Primary endpoints: Number of patients with ablation at 1 week, R2 value of ablated lesion depth at 1 week and 2 more. Started Jan 2022; status: recruiting.
02
Conditions
fibroadenomabreast cancer
Beyond the preview
Go deeper on NCT05219695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05219695.